Table 1. Baseline characteristics by YAP1 expression.
| Characteristics | YAP1-negative (n=152) | YAP1-positive (n=38) | P |
|---|---|---|---|
| Age (years) | 0.09 | ||
| <70 | 85 (55.9) | 27 (71.1) | |
| ≥70 | 67 (44.1) | 11 (28.9) | |
| Median [IQR] | 69 [62.5–75] | 64.5 [60–75] | 0.07 |
| Sex | 0.06 | ||
| Male | 126 (82.9) | 36 (94.7) | |
| Female | 26 (17.1) | 2 (5.3) | |
| ECOG PS | 0.06 | ||
| 0–1 | 110 (72.4) | 33 (86.8) | |
| 2–3 | 42 (27.6) | 5 (13.2) | |
| Smoking | 0.20 | ||
| Never-smoker | 9 (5.9) | 0 | |
| Current/former smoker | 143 (94.1) | 38 (100.0) | |
| VA Lung Study Group classification | 0.65 | ||
| LD | 58 (38.2) | 13 (34.2) | |
| ED | 94 (61.8) | 25 (65.8) | |
| TNM stage by AJCC 8th edition | 0.82 | ||
| I–II | 4 (2.6) | 4 (10.5) | |
| III | 56 (36.8) | 9 (23.7) | |
| IV | 92 (60.5) | 25 (65.8) | |
| Metastatic lesions (n=119 with ED) | |||
| Central nervous system | 23 (24.5) | 10 (40.0) | 0.12 |
| Liver | 25 (26.6) | 8 (32.0) | 0.59 |
| Bone | 41 (43.6) | 9 (36.0) | 0.49 |
| Pleural effusion | 39 (41.5) | 12 (48.0) | 0.55 |
| Lactate dehydrogenase (n=148) | 0.86 | ||
| Normal | 43 (36.1) | 10 (34.5) | |
| Elevated | 76 (63.9) | 19 (65.5) | |
| CD56 | 0.09 | ||
| Negative or weak | 3 (2.0) | 3 (7.9) | |
| Strong | 149 (98.0) | 35 (92.1) | |
| Synaptophysin (n=165) | 0.045 | ||
| Negative or weak | 18 (13.5) | 9 (28.1) | |
| Strong | 115 (86.5) | 23 (71.9) | |
| Chromogranin (n=102) | 0.056 | ||
| Negative or weak | 49 (57.6) | 14 (82.4) | |
| Strong | 36 (42.4) | 3 (17.6) | |
The variables are presented as number (%) if not otherwise specified. IQR, interquartile range; ECOG PS, Eastern Cooperative Oncology Group performance status; VA, Veterans Administration; LD, limited-stage disease; ED, extensive-stage disease; TNM, tumor-node-metastasis; AJCC, American Joint Committee on Cancer.